AMSTERDAM — For patients with diffuse cutaneous systemic sclerosis, an autoimmune disease for which there are few treatment options, lenabasum (JBT-101, Corbus Pharmaceuticals) shows potential, new ...

Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...

Following the 2017 American College of Rheumatology (ACR) Annual Meeting—held in San Diego, California, November 3-8—Medscape spoke with Hospital for Special Surgery rheumatologists Dr Robert F.

Scleroderma, or systemic sclerosis refers to a disorder in which the skin and connective tissues of the body start to thicken and harden because of the overproduction of a protein called collagen.

The investigational therapy will be used in Kyverna's KYSA-5 Phase 1/2 open-label, multicenter study to evaluate KYV-101 in adult patients with diffuse cutaneous systemic sclerosis (scleroderma) This ...

Q: My daughter, who is 14-years-old, was diagnosed with localized scleroderma about three years ago, and I am finding out that not much is known on this disease. Could you tell be about it? Does it ...

Q: My son's hands started to swell more than a year ago, then his fingers and forearms got real hard. Then the skin around his mouth stated to wrinkle. After that he started to have difficulty ...

Please provide your email address to receive an email when new articles are posted on . Nearly 10% of patients with systemic sclerosis had systemic sclerosis sine scleroderma, a subtype without skin ...

The study sample size consisted of 15 patients with early diffuse cutaneous systemic sclerosis -- patients with skin hardening and issues with organs. Of the total participants, 10 patients received 5 ...

The therapy is already being evaluated in patients with lupus nephritis and diffuse cutaneous systemic sclerosis. "We have seen firsthand the transformative effects of KYV-101 in MG patients treated ...